Journal Information
Most cited
77
Clinical treatment of cholangiocarcinoma: an updated comprehensive reviewAlessandra Elvevi, Alice Laffusa, Miki Scaravaglio, Roberta Elisa Rossi, Raffaella Longarini, Anna Maria Stagno, Laura Cristoferi, Antonio Ciaccio, ... Sara Massironi
Ann Hepatol. 2022;27:100737
77
Open access
47
From Child-Pugh to MELD score and beyond: Taking a walk down memory laneAndres Ruf, Melisa Dirchwolf, Richard B. Freeman
Ann Hepatol. 2022;27:100535
47
Open access
42
Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and CPegah Golabi, James M. Paik, Katherine Eberly, Leyla de Avila, Saleh A. Alqahtani, Zobair M. Younossi
Ann Hepatol. 2022;27:100556
42
Open access
34
The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based studyOsama Hamid, Ahmed Eltelbany, Abdul Mohammed, Khaled Alsabbagh Alchirazi, Sushrut Trakroo, Imad Asaad
Ann Hepatol. 2022;27:100727
34
Open access
29
Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p/c-Jun/SREBP-1c pathwaySi-Si Jin, Chun-Jing Lin, Xian-Fan Lin, Ju-Zeng Zheng, Hua-Qin Guan
Ann Hepatol. 2022;27:100584
29
Open access
26
Non-alcoholic fatty liver disease prevalence in Latin America: A systematic review and meta-analysisYesmi A. Ortega Rojas, Claudia L. Vidal Cuellar, Karina M. Aparicio Barrón, Juan Pablo Arab, Adelina Lozano Miranda
Ann Hepatol. 2022;27:100706
26
Full text access
23
Caffeine mitigates experimental nonalcoholic steatohepatitis and the progression of thioacetamide-induced liver fibrosis by blocking the MAPK and TGF-β/Smad3 signaling pathwaysEduardo E. Vargas-Pozada, Erika Ramos-Tovar, Consuelo Acero-Hernández, Irina Cardoso-Lezama, Silvia Galindo-Gómez, Víctor Tsutsumi, Pablo Muriel
Ann Hepatol. 2022;27:100671
23
Open access
22
NAFLD VS MAFLD. The evidence-based debate has come. Time to change?Diego García-Compeán, Alan Rafael Jiménez-Rodríguez
Ann Hepatol. 2022;27:100765
22
Full text access
21
Acid-base abnormalities and liver dysfunctionPeriklis Katopodis, Efthymios M. Pappas, Konstantinos P. Katopodis
Ann Hepatol. 2022;27:100675
21
Open access
21
miR-221-3p regulates hepatocellular carcinoma cell proliferation, migration and invasion via targeting LIFRWei Tan, Zhuokai Li, Weifen Xia, Jinde Zhu, Rengen Fan
Ann Hepatol. 2022;27 Supl 1:100567
21
Open access